ID28783A - Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain - Google Patents

Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain

Info

Publication number: ID28783A
Authority: ID; Indonesia
Prior art keywords: pemeka; modificated; antidiabetes; insulin; release
Prior art date: 1998-11-12

Application number

IDW00200101045A

Other languages

English (en)

Indonesian (id)

Inventor

Karen Lewis

Nicola Jayne Lilliott

Donald Colin Mackenzie

Vincenzo Re

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-12

Filing date

1999-11-08

Publication date

2001-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID28783(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-11-12 Priority claimed from GBGB9824869.3A external-priority patent/GB9824869D0/en

1998-11-12 Priority claimed from GBGB9824866.9A external-priority patent/GB9824866D0/en

1998-11-12 Priority claimed from GBGB9824867.7A external-priority patent/GB9824867D0/en

1999-05-25 Priority claimed from GBGB9912190.7A external-priority patent/GB9912190D0/en

1999-05-25 Priority claimed from GBGB9912193.1A external-priority patent/GB9912193D0/en

1999-05-25 Priority claimed from GBGB9912191.5A external-priority patent/GB9912191D0/en

1999-11-08 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-07-05 Publication of ID28783A publication Critical patent/ID28783A/id

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

IDW00200101045A 1998-11-12 1999-11-08 Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain ID28783A (id)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
GBGB9824869.3A GB9824869D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824866.9A GB9824866D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9824867.7A GB9824867D0 (en)	1998-11-12	1998-11-12	Novel composition and use
GBGB9912190.7A GB9912190D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912193.1A GB9912193D0 (en)	1999-05-25	1999-05-25	Novel composition and use
GBGB9912191.5A GB9912191D0 (en)	1999-05-25	1999-05-25	Novel composition and use

Publications (1)

Publication Number	Publication Date
ID28783A true ID28783A (id)	2001-07-05

Family

ID=27547326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW00200101045A ID28783A (id)	1998-11-12	1999-11-08	Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain

Country Status (36)

Country	Link
EP (3)	EP1813273A1 (de)
JP (1)	JP2002529504A (de)
KR (1)	KR100643833B1 (de)
CN (1)	CN1230162C (de)
AR (1)	AR024228A1 (de)
AT (1)	ATE406889T1 (de)
AU (1)	AU768994B2 (de)
BG (2)	BG109852A (de)
BR (1)	BR9915285A (de)
CA (1)	CA2351058A1 (de)
CY (1)	CY1108587T1 (de)
CZ (1)	CZ20011629A3 (de)
DE (1)	DE69939485D1 (de)
DK (1)	DK1131070T3 (de)
DZ (1)	DZ2936A1 (de)
EA (2)	EA200601145A1 (de)
ES (1)	ES2312221T3 (de)
HK (1)	HK1040910B (de)
HR (1)	HRP20010343B1 (de)
HU (1)	HUP0104303A3 (de)
ID (1)	ID28783A (de)
IL (2)	IL143002A0 (de)
MY (1)	MY124695A (de)
NO (1)	NO20012303L (de)
NZ (1)	NZ511614A (de)
OA (1)	OA11677A (de)
PE (1)	PE20001238A1 (de)
PL (1)	PL347634A1 (de)
PT (1)	PT1131070E (de)
SI (1)	SI1131070T1 (de)
SK (1)	SK287038B6 (de)
TR (1)	TR200101333T2 (de)
TW (2)	TWI251487B (de)
UY (1)	UY25799A1 (de)
WO (1)	WO2000028989A1 (de)
YU (1)	YU37301A (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6099862A (en) *	1998-08-31	2000-08-08	Andrx Corporation	Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en)	1999-11-16	2006-08-30	Smithkline Beecham Plc	Novel composition based on thiazolidinedione and metformin and use
HUP0600522A2 (en) *	1999-12-23	2006-11-28	Novartis Ag	Use of hypoglycemic agent for treating impaired glucose metabolism
AU2007201729B2 (en) *	1999-12-23	2010-02-25	Novartis Ag	Use of hypoglycemic agent for treating impaired glucose metabolism
US6761901B1 (en)	2000-05-02	2004-07-13	Enzrel Inc.	Liposome drug delivery
US8257744B2 (en) *	2000-07-07	2012-09-04	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
FR2811227A1 (fr) *	2000-07-07	2002-01-11	Philippe Maincent	Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US6866866B1 (en) *	2000-11-03	2005-03-15	Andrx Labs, Llc	Controlled release metformin compositions
BR0115390A (pt) *	2000-11-03	2004-02-25	Andrx Corp	Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
US6790459B1 (en)	2000-11-03	2004-09-14	Andrx Labs, Llc	Methods for treating diabetes via administration of controlled release metformin
FR2816840B1 (fr)	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
CA2434169C (en) *	2001-01-12	2011-03-15	Sun Pharmaceutical Industries Limited	Spaced drug delivery system
NZ527930A (en) *	2001-03-16	2005-11-25	Andrx Pharmaceuticals Llc	Controlled release sulfonylurea formulation
FR2822069B1 (fr) *	2001-03-19	2003-06-20	Lipha	Composition pharmaceutique comprenant un compose stimulant la secretion d'insuline et un derive de thiazolidinedione et son utilisation pour la preparation de medicamments destines a traiter le diabete
AU2002314968B2 (en) *	2001-06-08	2006-12-07	Endo Pharmaceuticals, Inc.	Controlled release dosage forms using acrylic polymer, and process for making the same
MXPA04000181A (es) *	2001-07-10	2004-11-22	Kos Life Sciences Inc	Formulacion de nucleo que comprende troglitazona y una biguanida.
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
US7183321B2 (en) *	2001-12-17	2007-02-27	Bristol-Myers Squibb Company	Antidiabetic formulation and method
JP2005523249A (ja)	2002-01-09	2005-08-04	エンズレルインコーポレイテッド	多環式芳香族抗酸化剤または抗炎症化合物のリポソーム薬物配達
PE20030800A1 (es) *	2002-02-12	2003-10-31	Glaxo Group Ltd	Forma de dosificacion oral de liberacion controlada
EP1492511B3 (de)	2002-04-09	2012-05-02	Flamel Technologies	Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US8911781B2 (en) *	2002-06-17	2014-12-16	Inventia Healthcare Private Limited	Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en)	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en)	2002-09-20	2011-12-27	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en)	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
EP1589951B1 (de) *	2003-01-03	2017-08-09	Supernus Pharmaceuticals, Inc.	Verwendung eines gemisches aus zwei oder mehr enterischen stoffen zur regulierung der arzneimittelfreisetzung über eine membran oder matrix für systemische therapeutika
EP1588708A4 (de)	2003-01-29	2006-03-01	Takeda Pharmaceutical	Verfahren zur herstellung einer beschichteten zubereitung
PE20050335A1 (es) *	2003-08-07	2005-06-01	Sb Pharmco Inc	Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition
GB0320522D0 (en)	2003-09-02	2003-10-01	Glaxo Group Ltd	Formulation
CA2540225C (en)	2003-10-31	2012-03-06	Takeda Pharmaceutical Company Limited	Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
EP1738754B1 (de)	2004-04-14	2015-07-15	Takeda Pharmaceutical Company Limited	Feste pharmazeutische zubereitung
AU2004318976B2 (en) *	2004-04-29	2009-04-09	Lotus Pharmaceutical Co., Ltd.	Oral modified-release lozenges and their preparation method
CN1327840C (zh) *	2004-06-08	2007-07-25	天津药物研究院	一种药物组合物及其在制备用于治疗糖尿病中的应用
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
KR100657785B1 (ko) *	2005-02-19	2007-04-16	한국유나이티드제약 주식회사	글리메피리드, 메트포르민 및 은행엽엑스를 함유하는 약학적 조성물
US20060222709A1 (en) *	2005-03-18	2006-10-05	Agi Therapeutics Research Ltd.	Metformin methods and formulations for treating chronic constipation
MXPA05010977A (es) *	2005-10-12	2007-04-11	Abdala Leopoldo Espinosa	Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus.
MXPA05014092A (es) *	2005-12-20	2007-06-20	Leopoldo De Jesus Espinosa Abdala	Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2.
AR058605A1 (es) *	2005-12-22	2008-02-13	Takeda Pharmaceutical	Preparacion solida
TW200816995A (en) *	2006-08-31	2008-04-16	Daiichi Sankyo Co Ltd	Pharmaceutical composition containing insulin sensitizers
KR100812538B1 (ko) *	2006-10-23	2008-03-11	한올제약주식회사	약물 제어방출형 메트포르민-글리메피리드 복합제제
CA2673111A1 (en) *	2006-12-07	2008-06-19	Schering Corporation	Ph sensitive matrix formulation
ATE476176T1 (de) *	2007-03-02	2010-08-15	Farnam Co Inc	Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
TW200906383A (en) *	2007-08-02	2009-02-16	Handok Pharmaceuticals Co Ltd	Sustained-release formulation comprising metformin acid salt
RS56990B1 (sr)	2007-09-10	2018-05-31	Janssen Pharmaceutica Nv	Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
US8802156B2 (en)	2007-11-14	2014-08-12	Laboratorios Farmacéuticos Rovi, S.A.	Pharmaceutical forms for the release of active compounds
CN101548961B (zh) *	2008-04-03	2011-05-04	单宝华	一种治疗糖尿病及肥胖症的口服胶囊制剂
WO2010026467A2 (en) *	2008-09-04	2010-03-11	Torrent Pharmaceuticals Ltd.	Controlled release dosage form of high solubility active ingredient
US9056850B2 (en)	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
KR101189639B1 (ko) *	2008-12-15	2012-10-12	씨제이제일제당 (주)	메트포르민 및 α-글리코시다제 억제제를 포함하는 경구 제제 및 그 제조방법
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
HUE031375T2 (en)	2009-10-14	2017-07-28	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
SG10201506114UA (en)	2010-05-11	2015-09-29	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
EP2590631B1 (de) *	2010-07-06	2016-10-26	Janssen Pharmaceutica NV	Formulierung zur kombinierten behandlung von diabetes
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
EP2661266B1 (de)	2011-01-07	2020-09-16	Anji Pharma (US) LLC	Auf chemosensorischen rezeptorliganden basierende therapien
EP2697218B1 (de)	2011-04-13	2016-05-25	Janssen Pharmaceutica NV	Verfahren zur herstellung von verbindungen die als sglt2 inhibitoren verwendbar sind
TWI542596B (zh)	2011-05-09	2016-07-21	健生藥品公司	（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
KR20190120430A (ko) *	2012-01-06	2019-10-23	엘셀릭스 테라퓨틱스 인코포레이티드	바이구아나이드 조성물 및 대사 장애를 치료하는 방법
EP2800562A2 (de)	2012-01-06	2014-11-12	Elcelyx Therapeutics, Inc.	Zusammensetzungen und verfahren zur behandlung von stoffwechselstörungen
CN102631332A (zh) *	2012-04-28	2012-08-15	邹立兴	一种伏格列波糖片剂及其制备方法
KR101409330B1 (ko) *	2012-05-11	2014-06-18	안국약품 주식회사	복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP2958548A1 (de) *	2013-02-19	2015-12-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Verfahren zur herstellung von gliclazid-formulierungen
KR101937069B1 (ko) *	2014-12-17	2019-04-03	엠프로스 파마 악티에볼라그	비만 및 관련 대사 장애의 치료를 위한 오를리스타트 및 아카르보스의 변형 방출형 조성물
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105963280B (zh) *	2016-06-30	2018-11-06	合肥华方医药科技有限公司	一种伏格列波糖口腔速溶膜及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en)	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS5697277A (en)	1980-01-07	1981-08-05	Takeda Chem Ind Ltd	Thiazolidine derivative
US4538469A (en) *	1983-07-29	1985-09-03	Panametrics, Inc.	Integrated threshold arming method and apparatus
JPS6051189A (ja)	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
US4582839A (en)	1984-03-21	1986-04-15	Takeda Chemical Industries, Ltd.	2,4-thiazolidinediones
CN1003445B (zh)	1984-10-03	1989-03-01	武田药品工业株式会社	噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da)	1985-02-26	2000-08-07	Sankyo Co	Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja)	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en)	1986-07-24	1989-03-14	Takeda Chemical Industries, Ltd.	Method for producing thiazolidinedione derivatives
EP0842925A1 (de) *	1987-09-04	1998-05-20	Beecham Group Plc	Substituierte Thiazolidindionderivate
US4791125A (en)	1987-12-02	1988-12-13	Pfizer Inc.	Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
MX15171A (es)	1988-03-08	1993-05-01	Pfizer	Derivados de tiazolidinodiona hipoglicemicos
WO1989008650A1 (en)	1988-03-08	1989-09-21	Pfizer Inc.	Thiazolidinedione hypoglycemic agents
IL91398A (en) *	1988-08-30	1994-05-30	Pfizer	Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
WO1991007107A1 (en)	1989-11-13	1991-05-30	Pfizer Inc.	Oxazolidinedione hypoglycemic agents
JP2630016B2 (ja) *	1990-05-21	1997-07-16	ヤマハ株式会社	吹奏感付加器を有する電子管楽器
US5089514A (en)	1990-06-14	1992-02-18	Pfizer Inc.	3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en)	1990-07-03	1994-07-28	Yamanouchi Pharma Co Ltd	Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
WO1992003425A1 (en)	1990-08-23	1992-03-05	Pfizer Inc.	Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja)	1990-12-06	1992-07-31	Terumo Corp	チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5183823A (en)	1991-04-11	1993-02-02	Takeda Chemical Industries, Ltd.	Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
DE69231886T2 (de)	1991-04-11	2002-03-28	Pharmacia & Upjohn Co., Kalamazoo	Thiazolidindionderivate, herstellung und anwendung
US5502078A (en) *	1991-05-28	1996-03-26	Zeneca Limited	Chemical compounds
TW222626B (de)	1991-07-22	1994-04-21	Pfizer
FR2680512B1 (fr)	1991-08-20	1995-01-20	Adir	Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja)	1992-03-26	1993-10-19	Japan Tobacco Inc	新規なトリアジン誘導体
US5264451A (en)	1992-04-07	1993-11-23	American Home Products Corporation	Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
EP0635007A1 (de)	1992-04-10	1995-01-25	Smithkline Beecham Plc	Heterocyclische derivate und ihre anwendung in der behandlung von type ii-diabetis
WO1993022445A1 (en)	1992-05-05	1993-11-11	The Upjohn Company	A process for producing pioglitazone metabolite
CZ1095A3 (en)	1992-07-03	1995-10-18	Smithkline Beecham Plc	Heterocyclic compounds, process of their preparation, their use for the preparation of a pharmaceutical preparation and the pharmaceutical composition containing thereof
US5232945A (en)	1992-07-20	1993-08-03	Pfizer Inc.	3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en)	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
RU2071783C1 (ru) *	1993-09-07	1997-01-20	Ессентукский центральный военный санаторий	Способ получения средства для лечения сахарного диабета
US5478852C1 (en)	1993-09-15	2001-03-13	Sankyo Co	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) *	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
GB9619757D0 (en) *	1996-09-21	1996-11-06	Knoll Ag	Chemical process
RU2114617C1 (ru) *	1996-09-27	1998-07-10	Юрий Георгиевич Каминский	Антидиабетическое средство на основе янтарной кислоты
JP2001521551A (ja) *	1997-03-24	2001-11-06	ガルデルマリサーチアンドデヴェロップメントエスエヌセ	インスリン非依存性糖尿病の治療のためのレチノイド関連分子
GB9715295D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment

1999
- 1999-11-08 CZ CZ20011629A patent/CZ20011629A3/cs unknown
- 1999-11-08 AU AU30338/00A patent/AU768994B2/en not_active Ceased
- 1999-11-08 EA EA200601145A patent/EA200601145A1/ru not_active IP Right Cessation
- 1999-11-08 PL PL99347634A patent/PL347634A1/xx not_active Application Discontinuation
- 1999-11-08 HK HK02101023.7A patent/HK1040910B/en not_active IP Right Cessation
- 1999-11-08 YU YU37301A patent/YU37301A/sh unknown
- 1999-11-08 CA CA002351058A patent/CA2351058A1/en not_active Abandoned
- 1999-11-08 WO PCT/EP1999/008704 patent/WO2000028989A1/en not_active Ceased
- 1999-11-08 AT AT99964483T patent/ATE406889T1/de active
- 1999-11-08 OA OA1200100117A patent/OA11677A/en unknown
- 1999-11-08 CN CNB998154792A patent/CN1230162C/zh not_active Expired - Fee Related
- 1999-11-08 EA EA200100541A patent/EA007610B1/ru not_active IP Right Cessation
- 1999-11-08 PT PT99964483T patent/PT1131070E/pt unknown
- 1999-11-08 EP EP07105992A patent/EP1813273A1/de not_active Withdrawn
- 1999-11-08 EP EP08163249A patent/EP1992337A1/de not_active Withdrawn
- 1999-11-08 JP JP2000582036A patent/JP2002529504A/ja not_active Ceased
- 1999-11-08 SI SI9931017T patent/SI1131070T1/sl unknown
- 1999-11-08 NZ NZ511614A patent/NZ511614A/en not_active IP Right Cessation
- 1999-11-08 ID IDW00200101045A patent/ID28783A/id unknown
- 1999-11-08 HR HR20010343A patent/HRP20010343B1/xx not_active IP Right Cessation
- 1999-11-08 BR BR9915285-1A patent/BR9915285A/pt not_active Application Discontinuation
- 1999-11-08 EP EP99964483A patent/EP1131070B1/de not_active Revoked
- 1999-11-08 IL IL14300299A patent/IL143002A0/xx unknown
- 1999-11-08 ES ES99964483T patent/ES2312221T3/es not_active Expired - Lifetime
- 1999-11-08 DE DE69939485T patent/DE69939485D1/de not_active Expired - Lifetime
- 1999-11-08 DK DK99964483T patent/DK1131070T3/da active
- 1999-11-08 TR TR2001/01333T patent/TR200101333T2/xx unknown
- 1999-11-08 KR KR1020017005967A patent/KR100643833B1/ko not_active Expired - Fee Related
- 1999-11-08 HU HU0104303A patent/HUP0104303A3/hu unknown
- 1999-11-08 SK SK644-2001A patent/SK287038B6/sk not_active IP Right Cessation
- 1999-11-10 AR ARP990105697A patent/AR024228A1/es unknown
- 1999-11-10 DZ DZ990236A patent/DZ2936A1/xx active
- 1999-11-11 MY MYPI99004896A patent/MY124695A/en unknown
- 1999-11-12 PE PE1999001146A patent/PE20001238A1/es not_active Application Discontinuation
- 1999-11-12 UY UY25799A patent/UY25799A1/es not_active Application Discontinuation
- 1999-12-24 TW TW093109152A patent/TWI251487B/zh not_active IP Right Cessation
- 1999-12-24 TW TW088122853A patent/TW592694B/zh not_active IP Right Cessation
2001
- 2001-05-07 IL IL143002A patent/IL143002A/en not_active IP Right Cessation
- 2001-05-10 NO NO20012303A patent/NO20012303L/no not_active Application Discontinuation
- 2001-06-07 BG BG109852A patent/BG109852A/bg unknown
- 2001-06-07 BG BG105568A patent/BG65351B1/bg unknown
2008
- 2008-11-24 CY CY20081101346T patent/CY1108587T1/el unknown

Also Published As

Publication number	Publication date
KR100643833B1 (ko)	2006-11-10
DZ2936A1 (fr)	2004-03-15
EA007610B1 (ru)	2006-12-29
CA2351058A1 (en)	2000-05-25
EA200100541A1 (ru)	2001-10-22
AR024228A1 (es)	2002-09-25
CN1348369A (zh)	2002-05-08
NZ511614A (en)	2003-12-19
IL143002A0 (en)	2002-04-21
BG65351B1 (bg)	2008-03-31
BG105568A (en)	2002-01-31
TWI251487B (en)	2006-03-21
HRP20010343A2 (en)	2002-06-30
WO2000028989A1 (en)	2000-05-25
SK6442001A3 (en)	2001-12-03
HK1040910B (en)	2009-06-26
EP1131070A1 (de)	2001-09-12
SI1131070T1 (sl)	2008-12-31
UY25799A1 (es)	2000-12-29
EP1131070B1 (de)	2008-09-03
CY1108587T1 (el)	2014-04-09
ES2312221T3 (es)	2009-02-16
PL347634A1 (en)	2002-04-22
AU768994B2 (en)	2004-01-15
BG109852A (bg)	2008-11-28
DK1131070T3 (da)	2008-11-17
PT1131070E (pt)	2008-11-19
DE69939485D1 (de)	2008-10-16
TW200418453A (en)	2004-10-01
NO20012303L (no)	2001-07-04
MY124695A (en)	2006-06-30
HUP0104303A3 (en)	2003-12-29
JP2002529504A (ja)	2002-09-10
EA011633B1 (ru)	2009-04-28
TR200101333T2 (tr)	2001-10-22
TW592694B (en)	2004-06-21
KR20010080419A (ko)	2001-08-22
HRP20010343B1 (hr)	2010-11-30
EA200601145A1 (ru)	2009-04-28
HUP0104303A2 (hu)	2002-03-28
EP1813273A1 (de)	2007-08-01
NO20012303D0 (no)	2001-05-10
YU37301A (sh)	2005-06-10
ATE406889T1 (de)	2008-09-15
HK1040910A1 (en)	2002-06-28
CN1230162C (zh)	2005-12-07
PE20001238A1 (es)	2001-01-11
EP1992337A1 (de)	2008-11-19
BR9915285A (pt)	2001-08-07
AU3033800A (en)	2000-06-05
SK287038B6 (sk)	2009-10-07
OA11677A (en)	2005-01-12
CZ20011629A3 (cs)	2001-12-12
IL143002A (en)	2007-02-11

Publication	Publication Date	Title
ID28783A (id)	2001-07-05	Komposisi farmasi untuk pelepasan termodifikasi dari pemeka insulin dan zat antidiabetes lain
ID27040A (id)	2001-02-22	Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
NO2011010I1 (no)	2011-06-20	Naproksen- og esomeprazoltabletter med modifisert frisetting
EE9700363A (et)	1998-06-15	Uus anesteseeriva toimega farmatseutiline segu
IS2004B (is)	2005-04-15	Lyfjasamsetningar sem innihalda vorikónasól
DE69935681D1 (de)	2007-05-10	Vorrichtungen zur Medikamentverabreichung
EE200000383A (et)	2001-12-17	Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
TR199800743A3 (tr)	1999-10-21	Ispençiyari uygulamaya mahsus devamli salivermeli polimer karisim matrisi.
BR9713237B1 (pt)	2009-01-13	comprimido de liberaÇço controlada de cloridrato de alfuzosina e composiÇço farmacÊutica compreendendo o mesmo.
ID26639A (id)	2001-01-25	Sediaan farmasi yang mengandung agonis reseptor angiotensin ii jenis 2 dan pemakaiannya
ATE234078T1 (de)	2003-03-15	Pharmazeutische omeprazol-formulierung
DE60043305D1 (de)	2009-12-24	Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DK1035833T3 (da)	2006-01-09	Sammensætning til nasal indgivelse
ID29350A (id)	2001-08-23	Komposisi farmasi untuk pelepasan terus menerus dan metode pelepasan zat aktif farmasi
DE69907885D1 (de)	2003-06-18	Spritze und Spritzenkolben
ID26773A (id)	2001-02-08	Sulfur tersubstitusi pada asam sulfonilaminokarboksilat n-arilamida, persiapan, penggunaan dan persiapan pembuatan obat yang menyertainya
DK1066049T3 (da)	2003-09-29	Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
ATE331529T1 (de)	2006-07-15	Antigen enthaltende pharmazeutische zusammensetzung
EE200100391A (et)	2002-10-15	Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
IL156262A0 (en)	2004-01-04	Anti-cd28 antibodies having no mitogenic activity and pharmaceutical compositions containing the same
ECSP045171A (es)	2004-08-27	Régimen de dosificación y composición farmacéutica para anticoncepción de emergencia
NO995251D0 (no)	1999-10-27	FremgangsmÕte for administrering av haloterapi
NO20001375D0 (no)	2000-03-16	Legemiddelformulering med kontrollert virkestoffrigivning
PL361518A1 (pl)	2004-02-09	Zastosowanie substancji oraz kompozycja farmaceutyczna
PL348153A1 (en)	2002-05-06	Pharmaceutical composition for modified release insulin sensitiser